Mourad Chaari
Overview
Explore the profile of Mourad Chaari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
64
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maaloul I, Kolsi R, Chaari M, Ameur S, Aloulou H, Kamoun T
Tunis Med
. 2024 Nov;
102(11):916-921.
PMID: 39564636
Objective: the aim of this study is to report epidemiological data, clinical presentations and management of chronic immune thrombocytopenic purpura (ITP) in a single center in south of TUNISIA. Methods:...
2.
Abida F, Ben Salah R, Chaari M, Koubaa M, Ben Jemaa M, Elleuch H, et al.
Curr Res Transl Med
. 2024 Jul;
72(4):103459.
PMID: 39002408
Objective: The aim of our study is to describe the epidemiological, clinical, biological, etiological and evolutionary profile of HLH in Tunisia. Methods: A retrospective study that involved patients, with images...
3.
Jedidi I, Krichen I, Chaari M, Louati N, Mdhaffar M
Br J Haematol
. 2023 Mar;
201(3):378.
PMID: 36942612
No abstract available.
4.
Louati N, Fakhfakh Y, Chaari M, Rekik T, Kassar O, Elloumi M, et al.
Ann Biol Clin (Paris)
. 2022 Dec;
80(5):471-477.
PMID: 36453736
Primary plasma leukemia is defined by the presence of more than 20% plasma cells in the peripheral blood or number of circulating plasma cells greater than 2G/L. It has points...
5.
Ameur S, Aloulou H, Wali M, Alibi S, Chaari M, Kallel C, et al.
Tunis Med
. 2016 Jan;
93(7):482-3.
PMID: 26757512
No abstract available.
6.
Chaari M, Ayadi I, Rousseau A, Lefkou E, Van Dreden P, Sidibe F, et al.
BMC Cancer
. 2014 Dec;
14:991.
PMID: 25535397
Background: In breast cancer patients routine thromboprophylaxis is not recommended but individualized risk assessment is encouraged. The incorporation of hypercoagulability biomarkers could increase the sensitivity of risk assessment models (RAM)...
7.
Chaari M, Bouhlel R, Kallel S, Aidi Z, Makni F, Gerotziafas G, et al.
Ann Biol Clin (Paris)
. 2012 Dec;
70(6):741-6.
PMID: 23207822
We report the case of a 19-year-old women who developed on post partum day 1 a large hematoma in the vaginal wall. A surgical intervention for evacuating the hematoma was...
8.
Gerotziafas G, Van Dreden P, Chaari M, Galea V, Khaterchi A, Lionnet F, et al.
Thromb Haemost
. 2012 Apr;
107(6):1044-52.
PMID: 22535498
Sickle cell disease (SCD) is linked to hypercoagulability and is characterised by high concentrations of erythrocyte-derived microparticles (Ed-MPs). However, the impact of procoagulant cell-derived microparticles on the thrombin generation process...
9.
Gerotziafas G, Zarifis J, Bandi A, Mossialos L, Galea V, Tsinopoulos G, et al.
Clin Appl Thromb Hemost
. 2012 Feb;
18(4):356-63.
PMID: 22311629
Identification of outpatients with high platelet reactivity (HPR) on antiplatelet treatment is an unmet need. The present study was conducted in healthy individuals (n = 50) and in outpatients with...
10.
Gerotziafas G, Baccouche H, Sassi M, Galea V, Chaari M, Hatmi M, et al.
Thromb Res
. 2011 Oct;
129(1):101-3.
PMID: 22000405
No abstract available.